Immunic (IMUX) director Neermann receives fully vested options on 25,370 shares

Rhea-AI Filing Summary

IMMUNIC, INC. director Joerg Neermann reported a grant of stock options on common stock. He received options on 25,370 shares at an exercise price of $10.90 per share, all of which are fully vested as of March 27, 2026.

The options were conditionally approved by the board on March 27, 2026, subject to stockholder approval of an amendment to the 2019 Omnibus Equity Incentive Plan. That approval was obtained at the 2026 Annual Meeting of Stockholders on June 29, 2026. Following the grant, this option position totals 25,370 shares and there are no remaining derivative holdings shown beyond this grant.

Insights

Equity compensation analyst

Routine fully vested option grant to Immunic director with no share sales.

The filing shows director Joerg Neermann receiving a stock option covering 25,370 shares of common stock at an exercise price of $10.90. The grant is compensation-related (code A) rather than an open-market trade, so it carries weak signaling value for near-term sentiment.

The options were fully vested as of March 27, 2026, and became effective after stockholders approved an amendment to the 2019 Omnibus Equity Incentive Plan at the 2026 Annual Meeting. With no reported purchases or sales and no additional derivative positions listed, this appears to be a standard board-approved equity award.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Neermann Joerg

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option	25,370	$0.00	--

Holdings After Transaction: Stock Option — 25,370 shares (Direct, null)

Footnotes (1)

1. Represents options to purchase shares of common stock conditionally approved by the Board of Directors on March 27, 2026, subject to approval of an amendment to the Company's 2019 Omnibus Equity Incentive Plan, as amended, by the Company's stockholders, which approval was obtained at the Company's 2026 Annual Meeting of Stockholders held on June 29, 2026. The option is fully vested as of March 27, 2026.

Key Figures

Option grant size: 25,370 shares Exercise price: $10.90 per share Total options after grant: 25,370 shares +3 more

6 metrics

Option grant size 25,370 shares Stock options on Immunic common stock granted to director

Exercise price $10.90 per share Exercise price of granted stock options

Total options after grant 25,370 shares Total shares underlying this option position following transaction

Vesting date March 27, 2026 Options fully vested as of this date

Expiration date March 27, 2036 Expiration of stock option grant

Shareholder approval date June 29, 2026 Approval of equity plan amendment at 2026 Annual Meeting

Key Terms

Stock Option, exercise price, 2019 Omnibus Equity Incentive Plan, Annual Meeting of Stockholders, +1 more

5 terms

Stock Option financial

"Represents options to purchase shares of common stock conditionally approved"

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

exercise price financial

"conversion_or_exercise_price": "10.9000""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

2019 Omnibus Equity Incentive Plan financial

"approval of an amendment to the Company's 2019 Omnibus Equity Incentive Plan, as amended"

Annual Meeting of Stockholders financial

"obtained at the Company's 2026 Annual Meeting of Stockholders held on June 29, 2026"

Grant, award, or other acquisition financial

"transaction_code_description": "Grant, award, or other acquisition""

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/29/2026 - 04:33 PM Accepted by SEC EDGAR 06/29/2026 - 04:32 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Neermann Joerg

(Last) (First) (Middle)

1200 AVENUE OF THE AMERICAS, SUITE 200

(Street)

NEW YORK NEW YORK 10036

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
IMMUNIC, INC. [ IMUX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	$10.9	06/29/2026		A		25,370(1)		(2)	03/27/2036	Common Stock	25,370	$0.00	25,370	D

Explanation of Responses:

1. Represents options to purchase shares of common stock conditionally approved by the Board of Directors on March 27, 2026, subject to approval of an amendment to the Company's 2019 Omnibus Equity Incentive Plan, as amended, by the Company's stockholders, which approval was obtained at the Company's 2026 Annual Meeting of Stockholders held on June 29, 2026.

2. The option is fully vested as of March 27, 2026.

	/s/ Joerg Neermann	06/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Immunic (IMUX) director Joerg Neermann report in this Form 4?

He reported receiving a stock option grant for 25,370 shares of Immunic common stock. The grant is a compensation-related award, not an open-market trade, and represents his entire option position shown in this filing following the transaction.

What is the exercise price of Joerg Neermann’s Immunic (IMUX) stock options?

The stock options carry an exercise price of $10.90 per share. This price is the amount he would pay per share to convert the options into Immunic common stock if he chooses to exercise them in the future.

When did Joerg Neermann’s Immunic (IMUX) stock options vest?

The options are fully vested as of March 27, 2026. Full vesting means he is immediately eligible to exercise all 25,370 options, subject to their terms and expiration date, without any further service or performance conditions.

Were Joerg Neermann’s Immunic (IMUX) option grants subject to stockholder approval?

Yes. The options were conditionally approved by the board on March 27, 2026, subject to stockholders approving an amendment to Immunic’s 2019 Omnibus Equity Incentive Plan. That approval occurred at the 2026 Annual Meeting of Stockholders on June 29, 2026.

Did Joerg Neermann buy or sell Immunic (IMUX) shares in this Form 4?

No open-market purchases or sales were reported. The Form 4 only shows a grant of stock options as compensation, coded as an acquisition (code A), with no corresponding sale transactions or tax-withholding dispositions disclosed.

What is the expiration date of Joerg Neermann’s Immunic (IMUX) stock options?

The options expire on March 27, 2036. After that date, any unexercised options will lapse and can no longer be converted into Immunic common stock, so the exercise decision must occur before this expiration.